Literature DB >> 8386424

5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences.

I Jansen1, J Olesen, L Edvinsson.   

Abstract

We have studied the regional distribution of 5-hydroxytryptamine (5-HT) receptor subtypes in fresh circular segments of human cerebral, middle meningeal, and temporal arteries. Vasomotor responses induced by a series of 5-HT agonists and antagonists with some degree of selectivity were studied by using a sensitive in vitro system. Nine 5-HT agonists were examined for contractile effects on the arteries. In cerebral and meningeal arteries 5-carboxamidotryptamine (5-CT) was more potent than 5-HT. The opposite order of potency (5-HT-5-CT) was found in temporal arteries. In the cerebral arteries 5-methoxytryptamine (5-MeOHT) was more potent than sumatriptan while sumatriptan was more potent than 5-MeOHT in meningeal and temporal arteries. The 5-HT1 receptor antagonist, methiothepin, competitively antagonized 5-CT-induced contractions in cerebral arteries, with a pA2 value of 9.05. 5-HT-induced contractions were competitively antagonized by ketanserin (5-HT2) in the temporal arteries pA2 value of 9.06). Methiothepin and ketanserin had non-competitive antagonistic effects in the middle meningeal arteries. The 5-HT3 selective antagonist ondansetron did not cause any shift of the contractions induced by 2-methyl-5-HT in the temporal, cerebral and middle meningeal arteries. These results suggest that the cerebral arteries mainly contain 5-HT1D or 5-HT1-like receptors, and the temporal artery 5-HT2 receptors; the data further indicate the presence of both receptor subtypes in the middle meningeal artery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386424     DOI: 10.1111/j.1748-1716.1993.tb09483.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  11 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.

Authors:  Peer Tfelt-Hansen; Kaj Seidelin; Michael Stepanavage; Christopher Lines
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

3.  Serotonin syndrome presenting as febrile encephalopathy with CSF pleocytosis: a report of three cases.

Authors:  Sanjay Prakash; Prayag Makwana; Chaturbhuj Rathore; Ankit Dave
Journal:  Neurol Sci       Date:  2016-06-20       Impact factor: 3.307

4.  Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry.

Authors:  T Nilsson; J Longmore; D Shaw; I J Olesen; L Edvinsson
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats.

Authors:  Y Nishimura
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Dilatation induced by 5-HT in the middle meningeal artery of the anaesthetised cat.

Authors:  Geoffrey Andrew Lambert; Cathy Donaldson; Karen Lisa Hoskin; Peter Michael Boers; Alessandro Stefano Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-05-07       Impact factor: 3.000

7.  Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs.

Authors:  R Verheggen; S Freudenthaler; F Meyer-Dulheuer; A J Kaumann
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

8.  Mediation by 5-HT1D receptors of 5-hydroxytryptamine-induced contractions of rabbit middle and posterior cerebral arteries.

Authors:  V Deckert; D Pruneau; J L Elghozi
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

9.  Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways.

Authors:  N Adham; L A Borden; L E Schechter; E L Gustafson; T L Cochran; P J Vaysse; R L Weinshank; T A Branchek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

10.  Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist.

Authors:  P De Vries; J P Heiligers; C M Villalón; P R Saxena
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.